European Archives - Page 119 of 1212 - European Medical Journal

Could Immunotherapy Change How We Treat Childhood Type 1 Diabetes?

Immunotherapy shows promise for improving glycaemic control in children with Type 1 diabetes.

Hidden Allergens Found in Common Medications

The study found gluten-derived excipients in 44.4% of analgesics and antipyretics.

US pharma tariffs: What they mean for drug prices

US drug tariffs may not hit branded prices hard, but generics and supply chains face disruption. Here’s what pharma leaders need to know.

The Role of Urine Biomarkers in Liver Cirrhosis Management

This recent study assessed the potential of urinary biomarkers to predict patient mortality in cirrhotic individuals.

Open-Source AI Tool Enhances Precision in Parkinson’s Disease Monitoring

Researchers have developed an AI tool that offers precise, objective monitoring of Parkinson’s motor symptoms.

Methotrexate-Tacrolimus Combo Reduces Rheumatoid Arthritis Relapse Risk

Patients with rheumatoid arthritis who stopped TNF inhibitors experienced fewer flares and treatment failures on methotrexate-tacrolimus therapy compared to methotrexate alone, with no major safety concerns.

World’s First Live Birth Achieved Through Remotely Operated ICSI System

A new case report documents the first live birth following fertilization by a fully automated, remotely operated intracytoplasmic sperm injection (ICSI) system, showcasing a breakthrough in assisted reproductive technology.

Global Study Reveals Stark Differences in Female Cancer Burden Across Regions

A new global study analyzing data from 1990 to 2021 uncovers significant regional disparities in female cancer burden. It highlights how risk factors like high BMI, poor diet, and unsafe sex drive the incidence of breast, cervical, and uterine cancers differently across socio-demographic levels.

EAU 2025 Interview: Maarten Albersen

As Chair, my main responsibilities include shaping the thematic structure and plenary sessions of the EAU Congress 2025, ensuring the…

Two-Year Cystic Fibrosis Therapy Shows Lasting Benefits

A new 96-week study confirms the long-term safety and sustained efficacy of elexacaftor/tezacaftor/ivacaftor in children with cystic fibrosis aged 6–11 years.